UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, DC 20549
FORM 8‑K
CURRENT REPORT PURSUANT TO
SECTION 13 OR 15(d) OF THE
SECURITIES EXCHANGE ACT OF 1934
Date of Report: October 30, 2018
(Date of earliest event reported)
BIOPHARMX CORPORATION
(Exact Name of Registrant as Specified in Its Charter)
Delaware
(State or Other Jurisdiction of Incorporation)
|
|
|
001-37411 |
| 59-3843182 |
(Commission File Number) |
| (IRS Employer Identification No.) |
1505 Adams Drive, Suite D Menlo Park, California |
|
94025 |
(Address of Principal Executive Offices) |
| (Zip Code) |
(650) 889-5020
(Registrant’s Telephone Number, Including Area Code)
Not Applicable
(Former name or former address, if changed since last report.)
Check the appropriate box below if the Form 8‑K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
|
|
☐ | Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
☐ | Soliciting material pursuant to Rule 14a‑12 under the Exchange Act (17 CFR 240.14a‑12) |
☐ | Pre‑commencement communications pursuant to Rule 14d‑2(b) under the Exchange Act (17 CFR 240.14d‑2(b)) |
☐ | Pre‑commencement communications pursuant to Rule 13e‑4(c) under the Exchange Act (17 CFR 240.13e‑4(c)) |
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 or Rule 12b-2 of the Securities Exchange Act of 1934.
|
|
|
|
|
| Emerging growth company | ☐ |
|
|
|
|
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 1.01 Entry into a Material Definitive Agreement.
On October 30, 2018, BioPharmX, Inc., a wholly-owned subsidiary of BioPharmX Corporation (the “Company”), and The Irvine Company LLC, entered into a Lease Agreement (“Lease”) for the lease of approximately 11,793 square feet of office and laboratory space located at 115 Nicholson Lane, San Jose, California, which will replace the Company’s current corporate headquarters. This facility will serve as the new principal executive office and laboratory for the Company. The term of the lease is for 5 years commencing on or about December 11, 2018. The Company’s initial monthly base rent obligation is $25,355, and the Company will also be obligated to pay its proportionate share of certain expenses associated with the maintenance, repair and operation of the facility.
The foregoing description is a summary, is not complete, and is qualified in its entirety by reference to the Lease, which is filed as Exhibit 10.1 to this Current Report on Form 8-K and incorporated herein by reference.
Item 9.01 Financial Statements and Exhibits
(d)
|
|
|
|
Exhibit No. | Description |
|
|
10.1 | Lease agreement between BioPharmX, Inc. and The Irvine Company LLC, dated October 30, 2018 |
|
|
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
|
|
|
|
| BIOPHARMX CORPORATION | ||
|
| ||
Date: October 31, 2018 | By: | /s/ David Tierney | |
|
| Name: | David Tierney |
|
| Title: | Chief Executive Officer |